Street View: How Pfizer makes up for patent expiries is key
BUZZ-Street View: How Pfizer makes up for patent expiries is key ** Pfizer PFE.N raised its full-year profit and revenue forecasts on Tuesday as demand for its cancer drug Padcev and blood thinner Eliquis led to higher-than-expected Q3 results
** 30 analysts rate Pfizer "hold" on average; median PT $29- LSEG-compiled data
PIPELINE OVER CLIFFSIDE
** Morgan Stanley ("equal weight," PT: $26) focused on pipeline execution, which it sees as key to replacing revenue lost from upcoming patent expirations
** Citigroup ("neutral," PT: $30) remains confident in co's dividend, but would not chase stock without better visibility beyond 2027-2029 patent-expiry period and further late-stage pipeline progress
** Morningstar (Fair Value: $32) sees potential for Pfizer to stand out in obesity market with once-monthly treatment option, though success will depend on tolerability
** Jefferies ("buy," PT: $36) says co's plans for all-oral treatment portfolio for hormone receptor-positive breast cancer could be important as drug Ibrance approaches loss of exclusivity
(Reporting by Akriti Shah in Bengaluru)
((akriti.shah@thomsonreuters.com ; X, formerly Twitter: @AkritiShahh))
Recent news on Pfizer
See all newsUS FDA approves Bayer's blood thinner to prevent repeat strokes
Street View: How Pfizer makes up for patent expiries is key
Pfizer Inc. reports results for the quarter ended September 30 - Earnings Summary
Pfizer raises 2026 forecasts as Eliquis, cancer drugs drive third-quarter results (updated)
Pfizer Q3 revenue beats estimates on new launches; raises guidance